Within the next 15 years, ADDF will help bring to market a new generation of drugs based on the #biologyofaging that can be combined with other therapies, including anti-amyloids, to defeat #Alzheimers thanks to a historic gift from the #Lauder family: bit.ly/3G3gNNG

More than 6.7M Americans and 57M people worldwide are living with #Alzheimers today. A new gift from the #Lauders ensures the #ADDF will be able to continue funding the most promising science around the globe until we defeat this disease: bit.ly/3G3gNNG

Thank you to all who joined the NSC Directors Symposium at #AGE2023! The session featured presentations from pilot grantees George Sutphin George Sutphin, Miranda Orr OrrLab, Andrey Parkhitko, Anna Dr. Anna Thalacker-Mercer, Danielle Bruns, Simone Sidoli, Maria Mihaylova, & Cristal M. Hill

A fun day 1 at #AAIC23 with aivi like the plant (she/her) Borna Bonakdarpour Maggie Flanagan M.D. OrrLab @JohnCraryMDPHD ☺️🧠🍨

Research from OrrLab shows that treatment to clear #senescent cells in #Alzheimer’s disease is safe in Phase I clinical trial. Learn more about the study, which appears in Nature Medicine. Alzheimer's Drug Discovery Foundation @nanostringtech  brnw.ch/21wCn5E

Exciting news! Led by @MitziGonzales, our team’s Phase I trial testing #senolytics in #Alzheimer’s disease reports on brain penetrance, safety, and biomarkers! 🧠 Phase 2 trial supported by Alzheimer's Drug Discovery Foundation is underway! #JoinOurStudy #SToMP-AD #Senescence #Aging nature.com/articles/s4159…

Results from a new study led by ADDF-funded OrrLab further validate that novel approaches to #Alzheimers centered around the biology of aging will guide the next generation of therapeutics. Read our statement on the senescent cell treatment study here: bit.ly/3RdEQjd

First feasibility study of orally-delivered #senolytic therapy in #Alzheimersdisease reports favorable safety data and penetrance of #dasatinib into the brain with a modest impact on Alzheimer’s and aging biomarkers Wake Forest University School of Medicine Mitzi Gonzales OrrLab nature.com/articles/s4159…

Last week's 9th Annual Melvin R. Goodes Prize Luncheon & symposium reflected on recent breakthroughs in #Alzheimers research. This year, the ADDF honored DxA-funded scientist, Dr. Rhoda Au for her work with #DigitalBiomarkers and #diagnostics for early Alzheimer's detection.

ADDF-funded OrrLab's #CombinationTherapy clinical trial on senescent cells supports the ADDF's core belief that the next generation of #Alzheimers drugs will be guided by #novel targets based on the #BiologyOfAging. More on the trial in McKnight's LTC News: bit.ly/3rgc2Mq

Happy to share our latest publication - we used spatial proteomics to compare #PART and #AD looking at differences between NFTs, normal neurons and their microenvironments in the CA1 and CA2 subregions of the #hippocampus, as well as the entorhinal cortex. doi.org/10.1002/alz.13…

🧟 The OrrLab is researching senescent cells and their impact on memory problems. Could targeting "zombie" cells be a breakthrough in #Alzheimers treatments? Learn more: brnw.ch/21wD7Hq

Thrilled to help Jamie Walker, MD, PhD and her team explore differences in NFTs between #PART and #AD using GeoMx DSP! Awesome work! #nanostrung

It has been fun working with The Rainwater Charitable Foundation, Alzheimer's Association, CurePSP and other organizers to develop the scientific program for #Tau2024! My lab will be there - will yours? March 25-26, 2024 in Washington, DC. Register now: alz.org/Tau

I'm curio-s, it may be time to parse on 10x?

.⁦@nanostringtech⁩ is here to stay! Joe Beechem speaks up ⁦Genetic Engineering & Biotechnology News⁩: “We are not going anywhere”. Only #diversity will drive #innovation in Spatial Genomics! #youarenotalone genengnews.com/topics/omics/n…

TO ALL #spatial #genomics CEOs! Please read our Comment ⁦⁦Genetic Engineering & Biotechnology News⁩ “Sounding an Alarm over Spatial Biology” Scientists’ call for action. We are all part one community and have to act accordingly. Don’t let financial interests ruin innovation. genengnews.com/topics/biopers…

Thank you Alzheimer's Drug Discovery Foundation for bringing together at#ADPD2024 this impactful roundtable on Novel Approches in AD Research guided by the Biology of Aging with Miia Kivipelto Jacques Touchon Howard Fillit, MD Miranda Orr Wake Forest University Jeffrey Cummings

NanoString is excited to announce it will be acquired by Bruker Corporation in a $392.6 million agreement. We are grateful for our dedicated employees and customers! #futurelooksbright! bit.ly/3vMCkbz

Congratulations to the 10 Goodes Prize winners who along with the ADDF have shaped the last decade of #Alzheimers research around the #biologyofaging, moving the field closer to treating the disease with #precisionmedicine. Hope is here. bit.ly/3B9HPTG